Darou Darman Pars (DDP)

What Darou Darman Pars (DDP) does

Darou Darman Pars (DDP) is a privately held Iranian pharmaceutical manufacturer founded in 2000 and headquartered in Tehran, Iran. The company originated as an importer of active pharmaceutical ingredients (APIs) and has since evolved into a branded finished-dose producer operating specialized research and development and quality control laboratories. DDP manufactures both chemical and herbal medicines across ten therapeutic categories, including cardiovascular, anti-diabetic, gastrointestinal, neurology, infectious diseases, rare and metabolic diseases, men's health, pain and inflammation, respiratory and allergy, and opioid substitutes. Notable branded products include Koreno (Finerenone) for chronic kidney disease in type 2 diabetes, Rigaro (Rimegepant) for migraine, and Zyvolid (Linezolid) for resistant gram-positive infections, alongside herbal products such as Thymosan and Fizhitol.

The company operates a traditional sales-led go-to-market model, distributing prescription-only medicines through pharmacies and healthcare institutions in Iran, with a stated strategic emphasis on expanding international export markets. Marketing is conducted primarily through medical conferences, congress participation (such as the 25th Congress of Cardiovascular Updates), and a medical recommendations content section on the corporate website. Pricing is not publicly disclosed, consistent with prescription pharmaceutical industry norms. The company is privately held with no disclosed institutional investors, funding rounds, parent entities, or management team information in the available data, and operates with a disclosed headcount of approximately 40 employees. Recent activity in 2025, including six new product launches and an explicit focus on export market expansion, indicates a portfolio scaling and geographic growth phase.

Name

Darou Darman Pars (DDP)

Legal name

شرکت دارو درمان پارس (Darou Darman Pars Company)

Website

https://ddp-group.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Darou Darman Pars (DDP) is a privately held Iranian pharmaceutical manufacturer founded in 2000 that produces branded chemical and herbal medicines across ten therapeutic categories, distributing prescription products through pharmacies in Iran and selected international export markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industry

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Pharmaceutical manufacturing
• Herbal medicines
• Prescription drugs
• Cardiovascular medications
• Antibiotic formulations

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of chemical and herbal pharmaceutical products through domestic and international distribution channels

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Darou Darman Pars (DDP) is an Iranian pharmaceutical manufacturer that produces and distributes prescription-only chemical and herbal medicines across multiple therapeutic areas, including cardiovascular, anti-diabetic, neurological, infectious disease, pain management, gastrointestinal, respiratory/allergy, men's health, rare/metabolic disorders, and narcotic substitute categories. The company imports active pharmaceutical ingredients and manufactures branded finished dosage products that are sold through pharmacies and healthcare institutions domestically and exported to international markets.

Product overview

Darou Darman Pars (DDP) is an Iranian pharmaceutical company with over two decades of experience manufacturing chemical and herbal medicines. The company operates as a portfolio of branded pharmaceutical products organized across two main categories: chemical drugs and herbal drugs. The chemical drug portfolio covers multiple therapeutic areas including cardiovascular (e.g., Koreno/Finerenone for kidney and heart protection), anti-diabetic, gastrointestinal, neurology (e.g., Rigaro/Rimegepant for migraine), infectious diseases (e.g., Zyvolid/Linezolid antibiotic), men's health, pain/inflammation, respiratory/allergy, and metabolic/rare diseases. The herbal drug portfolio includes products like Thymosan and Fizhitol. DDP emphasizes importing active pharmaceutical ingredients and manufacturing quality products meeting international standards, with dedicated quality control and R&D laboratories.

Differentiator

Problem solved

Functional benefit

Products and services

• Rigaro (ریگارو) Rimegepant 75mg orally dissolving tablet used for immediate treatment of migraine attacks with or without aura in adults, and for prevention and reduction of episodic migraine frequency. A chemical drug for patients with neurological conditions, prescribed through physicians and dispensed via pharmacies.
• Koreno (کورنو) Finerenone tablet in 10mg and 20mg doses, a non-steroidal mineralocorticoid receptor antagonist indicated for reducing progression of chronic kidney disease in type 2 diabetes patients and reducing cardiovascular complications and heart failure outcomes. A chemical cardiovascular/diabetic drug for physician-prescribed dispensing.
• Zyvolid (زایولید) Linezolid 600mg coated tablet antibiotic used for treating resistant hospital-acquired pneumonia, bacteremia, complicated and uncomplicated gram-positive skin infections, diabetic foot infections, and vancomycin-resistant infections. A chemical antibiotic for hospital and outpatient infectious disease treatment.
• Thymosan (تیموزان) Herbal pharmaceutical product in DDP's herbal medicines portfolio, offered alongside chemical drugs for physician-prescribed dispensing through pharmacies.
• Fizhitol (فیژیتول) Herbal pharmaceutical product in DDP's herbal medicines portfolio, offered alongside chemical drugs for physician-prescribed dispensing through pharmacies.

Quantifiable outcome

• Production of quality pharmaceutical products meeting international standards

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Cipla: Indian multinational pharmaceutical company with broad generic portfolio spanning respiratory, cardiovascular, anti-infective, and CNS categories. Comparable in therapeutic breadth and emerging-market export orientation to DDP.
• Dr. Reddy's Laboratories: India-based global generics manufacturer with branded generics across cardiovascular, anti-diabetic, neurology, and specialty areas — directly overlapping with DDP's therapeutic categories. Relevant as a scaled reference for the export-oriented generic pharma business model.
• Aurobindo Pharma: Global Indian generic pharmaceutical manufacturer producing a wide branded-generic portfolio including antibiotics, cardiovascular, CNS, and specialty products. Comparable in generic-pharma manufacturing model and export ambitions to emerging markets, though at vastly greater scale.
• Hikma Pharmaceuticals: MENA-region-focused pharmaceutical company with strong branded generics and specialty presence across the Middle East and North Africa. Direct strategic comparable to DDP's stated ambition of expanding from Iranian base into regional export markets.

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer producing branded generics across multiple therapeutic areas for MENA markets. Comparable regional player with similar product-portfolio breadth and export-oriented growth strategy from a Gulf base.
• Pharmaline (Lebanon): Lebanese pharmaceutical manufacturer producing branded generics for MENA markets with focus on quality standards aligned with European regulators. Comparable as a regional emerging-market generic manufacturer with export ambitions similar to DDP's stated strategy.

Direct peers

• Barakat Pharmaceutical Company: Iranian manufacturer of branded generic medicines including cardiovascular, anti-diabetic, and specialty products. Comparable therapeutic-area breadth and distribution channel structure to DDP.
• Actoverco Pharmaceutical Company: Iranian generic pharmaceutical manufacturer producing chemical and biotech medicines across multiple therapeutic categories. Directly comparable in business model (domestic Iranian branded generics) and therapeutic breadth.
• TPICO (Tamin Pharmaceutical Industries): Iranian pharmaceutical holding company with manufacturing, distribution, and API production capabilities. Direct comparable given overlapping Iranian-domestic generic pharmaceutical focus and sales-led distribution through pharmacies.
• Darou Pakhsh Pharma Manufacturing Company: One of Iran's largest pharmaceutical manufacturers producing a broad portfolio of branded generics across cardiovascular, anti-infective, and other therapeutic areas. Directly comparable to DDP in product mix and domestic Iranian distribution model, but at materially greater scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks1 record

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/darou-darman-pars

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Darou Darman Pars (DDP)